(Q22252840)

3 August 2017

1 reference

title

NSAIDs for the chemoprevention of Alzheimer's disease (English)

1 reference

3 August 2017

1 reference

2

Terrence Town

Terrence

Town

1 reference

3 August 2017

Christine A. Szekely

1

Christine A

Szekely

1 reference

3 August 2017

Peter P. Zandi

series ordinal

3

author given names

Peter P

author last names

Zandi

1 reference

3 August 2017

publication date

1 January 2007

1 reference

Sub-cellular biochemistry

3 August 2017

published in

Subcellular Biochemistry

0 references

1 reference

3 August 2017

volume

42

1 reference

3 August 2017

page(s)

229-248

1 reference

Anti-inflammatory drugs protect against Alzheimer disease at low doses.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Effect of Anti-inflammatory Medications on Neuropathological Findings in Alzheimer Disease

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Alzheimer Disease in the US Population

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Risk of cardiovascular events associated with selective COX-2 inhibitors

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Alzheimer's disease: a study of epidemiological aspects.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

A case-control study of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Neuroinflammation in Alzheimer's disease and prion disease.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer's disease: function, regulation of proteolysis, and implications for drug development

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Methods for projecting the incidence and prevalence of chronic diseases in aging populations: application to Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Mechanisms of cell death in Alzheimer disease--immunopathology.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Does aspirin protect against Alzheimer's dementia? A study in a Swedish population-based sample aged > or =80 years

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Nonsteroidal antiinflammatory drug use in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Anti-inflammatory drugs and Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Rheumatoid arthritis and susceptibility to Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

In-vivo measurement of activated microglia in dementia

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Suppression of A beta-induced monocyte neurotoxicity by antiinflammatory compounds

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Double placebo design in a prevention trial for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Comparison of baseline characteristics and mortality experience of participants and nonparticipants in a randomized clinical trial: the Physicians' Health Study

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Inflammation and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Frequency of stages of Alzheimer-related lesions in different age categories

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Indomethacin reverses the microglial response to amyloid beta-protein

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

NSAIDs and incident Alzheimer’s disease. the Rotterdam study

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Inflammatory processes in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Selective inhibition of Abeta42 production by NSAID R-enantiomers

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Nonsteroidal drugs and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

COX-2 inhibitors--a lesson in unexpected problems

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

COX-2 inhibitors--lessons in drug safety

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Complement activation by beta-amyloid in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Special issues related to randomized trials of primary prevention

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Confounding by indication: an example of variation in the use of epidemiologic terminology

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

A case-control study of dementia of the Alzheimer type

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Rheumatoid arthritis and senile dementia of the Alzheimer's type.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Alzheimer's disease and rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Modulation of beta-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Assessment and control for confounding by indication in observational studies.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

The C-terminus of the beta protein is critical in amyloidogenesis

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Hormone replacement therapy, heart disease, and other considerations

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Alzheimer's disease: genes, proteins, and therapy

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

A case-control analysis of nonsteroidal anti-inflammatory drugs and Alzheimer's disease: are they protective?

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Long-term monitoring of insulin-like growth factor I in adult growth hormone deficiency: a critical appraisal.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

A case-control study of Alzheimer's disease in Australia

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

A case-control study of Alzheimer's disease in China

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Clinical trial of indomethacin in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

The Canadian Study of Health and Aging: risk factors for Alzheimer's disease in Canada

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Nonsteroidal anti-inflammatory drugs in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?: The Rotterdam Study

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Risk of Alzheimer's disease and duration of NSAID use.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Randomized pilot study of nimesulide treatment in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Cox-2 inhibitors and cardiovascular risk: we defend our data and suggest caution.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984.

1 reference

https://api.crossref.org/works/10.1007%2F1-4020-5688-5_11

7 January 2021

Identifiers

DOI

10.1007/1-4020-5688-5_11

0 references

1 reference